T1	Participants 164 227	patients with chronic heart failure after myocardial infarction
T2	Participants 560 618	patients with class II to IV HF and ejection fraction <35%
T3	Participants 770 888	Of 330 patients intended for enrollment, 23 were randomized (MARVEL-1) before stopping the study for financial reasons
T4	Participants 954 1005	group: 8 (placebo), 7 (low dose), and 8 (high dose)
T5	Participants 1423 1480	In HF patients with chronic postinfarction cardiomyopathy
